India’s fertility treatment market leader seeks Rs 90 crore for expansion as medical tourism set to increasae
Gaudium IVF and Women Health Ltd. is tapping the capital markets with a Rs 165 crore initial public offering, positioning itself as India’s first pure-play listed fertility treatment company. The issue, which opens for subscription on February 20, 2026, comes at a time when India’s IVF market is projected to more than triple from USD 1.32 billion in 2024 to USD 4.54 billion by 2034, registering a robust CAGR of 13.13%.
While the company has demonstrated strong growth momentum and operates a unique hub-and-spoke model across 30+ locations, the valuation is at a P/E of 30.04 on FY25 earnings.
IPO SNAPSHOT
| Parameter | Details |
|---|---|
| Issue Opens | February 20, 2026 |
| Issue Closes | February 24, 2026 |
| Price Band | Rs 75 – Rs 79 per share |
| Issue Size | 20,886,200 equity shares (Rs 165 crore at upper band) |
| Fresh Issue | 11,392,500 shares (Rs 90 crore) |
| Offer for Sale (OFS) | 9,493,700 shares (Rs 75 crore) |
| Face Value | Rs 5 per share |
| Lot Size | 189 shares |
| Listing | BSE and NSE |
| Post-Issue Shareholding | 28.70% of total equity |
| Market Cap (at upper band) | Rs 575.02 crore |
COMPANY OVERVIEW
Gaudium IVF and Women Health Ltd. operates across India’s fertility treatment landscape with a distinctive hub-and-spoke model that balances capital efficiency with geographic reach. The company currently operates 7 hub centers and 28 spoke locations, covering major metropolitan areas including Delhi (2 centers), Mumbai, Ludhiana, Srinagar, Patna, and Bangalore.
“Gaudium,” derived from the Latin word meaning joy and gladness, reflects the company’s core mission of helping couples overcome infertility challenges through personalized fertility treatments. The company offers a comprehensive suite of services including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), egg freezing, embryo cryopreservation, genetic testing, and laparoscopic surgeries.
The Medical Tourism Angle
A significant differentiator for Gaudium is its growing international patient base. The company treats patients from Canada, the United Kingdom, United States, Kenya, South Africa, and Oman—a testament to both its quality standards and India’s competitive pricing advantage in fertility treatments. This medical tourism revenue stream adds a premium layer to the domestic growth story.
OPERATIONAL METRICS
| Period | IVF Cycles Performed | OPD Visits | Employees |
|---|---|---|---|
| FY23 | 3,512 | 4,218 | – |
| FY24 | 3,711 | 7,208 | – |
| FY25 | 3,476 | 8,145 | – |
| H1 FY26 (Sept 30, 2025) | 1,824 | 3,859 | 117 |
The OPD visit growth from 4,218 in FY23 to 8,145 in FY25 represents a 93% increase over two years, indicating strong brand traction and patient pipeline development. However, the slight decline in IVF cycles from 3,711 in FY24 to 3,476 in FY25 bears watching, even as it may reflect seasonal variations or treatment timing differences.
FINANCIAL PERFORMANCE
| Fiscal Year | Total Income (Rs Cr) | Net Profit (Rs Cr) | PAT Margin (%) | RoCE (%) | EPS (Rs) |
|---|---|---|---|---|---|
| FY23 | 44.26 | 13.53 | 30.56 | 54.40 | – |
| FY24 | 48.15 | 10.32 | 21.43 | 38.74 | – |
| FY25 | 70.96 | 19.13 | 26.96 | 39.37 | – |
| H1 FY26 (Sept 30, 2025) | 49.75 | 12.51 | 25.14 | 21.03* | – |
*Annualized basis
Revenue Growth: The company posted impressive 47.3% revenue growth in FY25, accelerating from 8.8% in FY24. Annualizing H1 FY26 numbers suggests continued momentum with projected full-year revenue of approximately Rs 99.5 crore.
Profitability Dip in FY24: Net profit declined 23.7% year-on-year in FY24 despite revenue growth. Management attributes this to a change in accounting policy. The recovery in FY25 with 85.4% profit growth validates this explanation, though it raises questions about accounting volatility.
Margin Profile: PAT margins ranging from 21% to 30% are exceptional for a healthcare services business, reflecting the premium pricing power and capital-light nature of fertility treatments once infrastructure is established.
Return on Capital Employed: RoCE of 54.40% in FY23 and sustained levels above 38% indicate capital efficiency, though the H1 FY26 annualized RoCE of 21.03% suggests compression as expansion capex is deployed.
USE OF PROCEEDS
The Rs 90 crore fresh issue proceeds will be deployed as follows:
| Purpose | Amount (Rs Cr) | % of Fresh Issue |
|---|---|---|
| Capex for new IVF centers | 50.00 | 55.6% |
| Debt repayment/prepayment | 20.00 | 22.2% |
| Inorganic growth opportunities | Balance | – |
| General corporate purposes | Balance | – |
The Rs 50 crore earmarked for new center expansion signals aggressive growth intent. At an estimated Rs 7-10 crore per hub center based on historical capex patterns, this could fund 5-7 new hubs, representing significant capacity addition to the current 7-hub base.
The Rs 20 crore debt repayment will strengthen the balance sheet, while the allocation toward inorganic growth hints at potential acquisitions in a highly fragmented market with 2,000+ IVF centers in India.
VALUATIONÂ
| Metric | Value |
|---|---|
| Pre-Issue NAV (Sept 30, 2025) | Rs 9.59 per share |
| Post-Issue NAV (at upper band) | Rs 20.45 per share |
| P/BV (on pre-issue NAV) | 8.24x |
| P/BV (on post-issue NAV) | 3.86x |
| P/E (on FY25 earnings) | 30.04x |
| P/E (on annualized H1 FY26 earnings) | 22.97x |
| Average EPS (3-year) | Rs 2.49 |
| Average RoNW (3-year) | 43.81% |
Valuation Commentary:
The issue is priced at 30x FY25 earnings and 8.24x pre-issue book value. For context:
- Healthcare services peers in India typically trade at 25-40x earnings, but most are established hospitals or diagnostic chains with diversified revenue streams
- The first-mover advantage in the listed space could command a premium, similar to specialty healthcare IPOs that have historically rewarded early investors
- High RoE of 43.81% justifies some premium, but sustainability depends on maintaining margins while scaling
The compression to 23x on annualized FY26 earnings assumes the strong H1 momentum continues—a reasonable but not guaranteed assumption given seasonality in fertility treatments.
SHAREHOLDING PATTERN
Pre-Issue Capital Structure:
| Category | Details |
|---|---|
| Current Paid-up Capital | Rs 30.70 crore (61,40,000 shares of Rs 5 each) |
| Post-IPO Paid-up Capital | Rs 36.39 crore (72,78,250 shares) |
| Dilution | 28.70% |
Promoter Cost of Acquisition:
The average cost of acquisition for promoters/selling shareholders ranges from NIL to Rs 0.16 per share—a stark contrast to the Rs 75-79 asking price. The company issued bonus shares in the ratio of 30:1 in September 2024, which explains the negligible acquisition cost.
This 49,275% gain for promoters (from Rs 0.16 to Rs 79) is typical of first-generation entrepreneurs who built the business from scratch, but the Rs 75 crore OFS component means promoters are monetizing a meaningful portion at listing.
INDUSTRY OPPORTUNITY
Market Size and Growth:
According to the Infomerics Research Report cited in the offer document:
- Indian IVF Market (2024): USD 1.32 billion (~4.8% of global market)
- Projected Market (2034): USD 4.54 billion (~8.3% of global market)
- CAGR (2024-2034): 13.13%
This positions India as one of the fastest-growing IVF markets worldwide, driven by:
- Rising infertility rates due to lifestyle factors, delayed marriages, and medical conditions
- Increasing awareness and social acceptance of assisted reproductive technology
- Affordable pricing compared to Western markets, attracting medical tourism
- Growing middle-class income enabling access to premium healthcare
Competitive Landscape:
The offer document compares Gaudium with Progyny Inc. (US-listed) and Inspire IVF Public Co. Ltd. (Thailand-listed)—international comparables given the absence of listed peers in India. This is both an opportunity (first-mover advantage) and a risk (no established valuation benchmarks).
With 2,000+ IVF centers in India, the market remains highly fragmented. Gaudium’s hub-and-spoke model and brand positioning as a premium provider differentiate it, but regional and unorganized players compete aggressively on price.
RISKS TO CONSIDER
1. Regulatory and Ethical Considerations: The IVF industry faces evolving regulations around assisted reproductive technology, genetic testing, and surrogacy. Policy changes could impact operations or require additional compliance costs.
2. Execution Risk on Expansion: The aggressive Rs 50 crore capex plan assumes successful site identification, regulatory approvals, staff hiring, and patient acquisition—all in a compressed timeline. Delays could impact near-term earnings.
3. Concentration Risk: With only 7 hub centers currently operational, geographic or location-specific challenges could disproportionately impact performance until the network scales.
4. Margin Sustainability: The 25-30% PAT margins are exceptional but may compress as competition intensifies, pricing pressure increases, or new centers operate below optimal capacity during ramp-up.
5. Accounting Policy Changes: The FY24 earnings dip attributed to accounting policy changes introduces uncertainty around earnings quality and reporting consistency.
6. Limited Operating History: As a relatively young company in growth mode, Gaudium lacks the multi-cycle track record of more established healthcare players.
ISSUE MANAGEMENT
| Role | Entity |
|---|---|
| Book Running Lead Manager (BRLM) | Sarthi Capital Advisors Pvt. Ltd. |
| Registrar to the Issue | Bigshare Services Pvt. Ltd. |
BRLM Track Record:
Sarthi Capital Advisors has handled 7 public issues in the past three years, of which 2 closed below the issue price on listing day—a 71% success rate. This is decent but not exceptional, suggesting investors should focus on fundamentals rather than relying on listing gains.
